Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,487 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.
Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, Plimack ER, Vaena D, Grimm MO, Bracarda S, Arranz JÁ, Pal S, Ohyama C, Saci A, Qu X, Lambert A, Krishnan S, Azrilevich A, Galsky MD. Sharma P, et al. Among authors: lambert a. Lancet Oncol. 2017 Mar;18(3):312-322. doi: 10.1016/S1470-2045(17)30065-7. Epub 2017 Jan 26. Lancet Oncol. 2017. PMID: 28131785 Clinical Trial.
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.
Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR, Vaishampayan UN, Drabkin HA, George S, Logan TF, Margolin KA, Plimack ER, Lambert AM, Waxman IM, Hammers HJ. Motzer RJ, et al. Among authors: lambert am. J Clin Oncol. 2015 May 1;33(13):1430-7. doi: 10.1200/JCO.2014.59.0703. Epub 2014 Dec 1. J Clin Oncol. 2015. PMID: 25452452 Free PMC article. Clinical Trial.
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH Jr, Lao CD, Linette GP, Thomas L, Lorigan P, Grossmann KF, Hassel JC, Maio M, Sznol M, Ascierto PA, Mohr P, Chmielowski B, Bryce A, Svane IM, Grob JJ, Krackhardt AM, Horak C, Lambert A, Yang AS, Larkin J. Weber JS, et al. Among authors: lambert a. Lancet Oncol. 2015 Apr;16(4):375-84. doi: 10.1016/S1470-2045(15)70076-8. Epub 2015 Mar 18. Lancet Oncol. 2015. PMID: 25795410 Clinical Trial.
Postnatal growth of etiologically characterized preterm newborns according to gestational age at birth.
Roggero P, Ryumina I, Gunier RB, Winsey A, Rauch SA, Zarco IAC, Ariff S, Rego MAS, Conti CS, Ochieng R, Tuzun F, Asibey J, Giuliani F, Renau MI, Shekharappa CB, Lapillonne A, Tavcioska G, Ismail LC, Menis C, Markelova M, Nieto R, Duah JA, Deantoni S, Madrid BF, Mosca F, Eskenazi B, Lambert A, Bhutta Z, Papageorghiou A, Kennedy S, Villar J. Roggero P, et al. Among authors: lambert a. Pediatr Res. 2024 Nov 28. doi: 10.1038/s41390-024-03735-x. Online ahead of print. Pediatr Res. 2024. PMID: 39609613
Endocrine management of transgender adolescents: Expert consensus of the french society of pediatric endocrinology and diabetology working group.
Brezin F, Busiah K, Leroy C, Fiot E, Bensignor C, Amouroux C, Caquard M, Cartault A, Castets S, Delcour C, Devernay M, Feigerlova E, Hoarau M, Lebon-Labich B, Lambert AS, Rouleau S, Trouvin MA, Vautier V, Martinerie L. Brezin F, et al. Among authors: lambert as. Arch Pediatr. 2024 Nov 16:S0929-693X(24)00176-3. doi: 10.1016/j.arcped.2024.08.003. Online ahead of print. Arch Pediatr. 2024. PMID: 39551654 Free article.
1,487 results